scholarly journals Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance

2018 ◽  
Vol 46 (7) ◽  
pp. 989-1000 ◽  
Author(s):  
Tom De Bruyn ◽  
Ayşe Ufuk ◽  
Carina Cantrill ◽  
Rachel E. Kosa ◽  
Yi-an Bi ◽  
...  
2003 ◽  
Vol 285 (5) ◽  
pp. G829-G839 ◽  
Author(s):  
Soichiro Hata ◽  
Pijun Wang ◽  
Nicole Eftychiou ◽  
Meenakshisundaram Ananthanarayanan ◽  
Ashok Batta ◽  
...  

Transport of a series of3H-radiolabeled C23, C24, and C27bile acid derivatives was compared and contrasted in HeLa cell lines stably transfected with rat Na+/taurocholate cotransporting polypeptide (ntcp) or organic anion transporting polypeptide 1 (oatp1) in which expression was under regulation of a zinc-inducible promoter. Similar uptake patterns were observed for both ntcp and oatp1, except that unconjugated hyodeoxycholate was a substrate of oatp1 but not ntcp. Conjugated bile acids were transported better than nonconjugated bile acids, and the configuration of the hydroxyl groups (α or β) had little influence on uptake. Although cholic and 23 norcholic acids were transported by ntcp and oatp1, other unconjugated bile acids (chenodeoxycholic, ursodeoxycholic) were not. In contrast to ntcp, oatp1-mediated uptake of the trihydroxy bile acids taurocholate and glycocholate was four- to eightfold below that of the corresponding dihydroxy conjugates. Ntcp mediated high affinity, sodium-dependent transport of [35S]sulfobromophthalein with a Kmsimilar to that of oatp1-mediated transport of [35S]sulfobromophthalein ( Km= 3.7 vs. 3.3 μM, respectively). In addition, for both transporters, uptake of sulfobromophthalein and taurocholic acid showed mutual competitive inhibition. These results indicate that the substrate specificity of ntcp is considerably broader than previously suspected and caution the extrapolation of transport data obtained in vitro to physiological function in vivo.


2013 ◽  
Vol 305 (12) ◽  
pp. C1223-C1229 ◽  
Author(s):  
Aisha L. Walker ◽  
Cynthia S. Lancaster ◽  
David Finkelstein ◽  
Russell E. Ware ◽  
Alex Sparreboom

Hydroxyurea is currently the only FDA-approved drug that ameliorates the pathophysiology of sickle cell anemia. Unfortunately, substantial interpatient variability in the pharmacokinetics (PK) of hydroxyurea may result in variation of the drug's efficacy. However, little is known about mechanisms that modulate hydroxyurea PK. Recent in vitro studies identifying hydroxyurea as a substrate for organic anion transporting polypeptide (OATP1B) transporters prompted the current investigation assessing the role of OATP1B transporters in modulating hydroxyurea PK. Using wild-type and Oatp1b knockout (Oatp1b−/−) mice, hydroxyurea PK was analyzed in vivo by measuring [14C]hydroxyurea distribution in plasma, kidney, liver, urine, or the exhaled14CO2metabolite. Plasma levels were significantly reduced by 20% in Oatp1b−/−mice compared with wild-type (area under the curve of 38.64 or 48.45 μg·h−1·ml−1, respectively) after oral administration, whereas no difference was observed between groups following intravenous administration. Accumulation in the kidney was significantly decreased by twofold in Oatp1b−/−mice (356.9 vs. 748.1 pmol/g), which correlated with a significant decrease in urinary excretion. Hydroxyurea accumulation in the liver was also decreased (136.6 vs. 107.3 pmol/g in wild-type or Oatp1b−/−mice, respectively) correlating with a decrease in exhaled14CO2. These findings illustrate that deficiency of Oatp1b transporters alters the absorption, distribution, and elimination of hydroxyurea thus providing the first in vivo evidence that cell membrane transporters may play a significant role in modulating hydroxyurea PK. Future studies to investigate other transporters and their role in hydroxyurea disposition are warranted for understanding the sources of variation in hydroxyurea's PK.


2019 ◽  
Author(s):  
Nivin N. Nyström ◽  
Lawrence C.M. Yip ◽  
Jeffrey J.L. Carson ◽  
Timothy J. Scholl ◽  
John A. Ronald

ABSTRACTPhotoacoustic imaging (PAI) combines optical contrast with the resolution and depth-detection of ultrasound and is increasingly being utilized for medical imaging in patients. PAI reporter genes would allow for monitoring of cell and gene therapies, but current reporters have immunogenicity and/or toxicity concerns that may limit clinical translation. Here we report a PAI reporter system employing the ability of human organic anion transporting polypeptide 1b3 (Oatp1b3) to take up the clinical dye indocyanine green (ICG) into cells. Following ICG administration, cells synthetically expressing Oatp1b3 exhibited significantly increased PAI signals compared to control cells both in vitro and in mice. Several benefits of this technology are the human derivation of Oatp1b3, and the high extinction coefficient, low quantum yield and pre-existing clinical approval of ICG. We posit that the Oatp1b3-ICG reporter system could be useful for in vivo gene and cell tracking in preclinical and clinical applications.


Sign in / Sign up

Export Citation Format

Share Document